Researchers are hopeful that psilocybin will bring relief to long term sufferers of anxiety, depression and terminally ill patients
Psilocybin has been used effectively to bring relief to those who are in the final stages of death.
Now it is being considered as a treatment for other stress-related diseases.
Used as a hallucinogenic for centuries, psilocybin is now being clinically tested for use medicinal use.
Legislators are also considering the legalization of the drug.
A British company dealing in mental health treatments announced that the FDA has granted them “breakthrough therapy designation” so that they can officially begin trialing psilocybin.
It seems that the federal government is entertaining the idea of using magic mushrooms for therapy, according to Rolling Stone magazine.
Charles Grob, a psychiatry and behavioral sciences professor at UCLA, told reporters that this represents a significant development in the whole history of psychedelic research.
He has been researching the unique qualities of magic mushrooms for two decades.
Government Interest In Research Results
Despite the research being conducted since 1990, the United States Government has only been seriously considering the potential benefits of psilocybin since August 2017.
The u-turn in the thinking about the use of magic mushrooms in therapy is a significant breakthrough.
It came as a result of proof that has emerged about the benefits they offer for people who suffer from anxiety and depression.
Rick Doblin, of the Multidisciplinary Association of Psychedelic Studies (MAPS), has been campaigning relentlessly for magic mushrooms to recognized as a legitimate therapy.
He has been a pioneer in the struggle and believes that psilocybin could be legalized as early as 2021.
If Compass Pathways makes good progress with the trials, the FDA is certain to give their approval.
This will be welcome news to people who have endured suffering resulting from nervous tension.
For some, prescription antidepressants do not bring the relief they so desperately need. This welcome news comes with a health warning from Doblin.
As pleased as he is that sufferers of depression may soon see a light at the end of the tunnel, he does not recommend that it becomes the go-to method for every patient who suffers from depression or anxiety.
Psilocybin should only be dispensed by therapists who have been explicitly trained in psychedelic psychotherapy.